Cancer Vaccines: Preclinical Studies and Novel Strategies

Advances in Cancer Research

Volumn 95, Issue , 2006, Pages 115-145

  Palena, Claudia ^a   Abrams, Scott I ^a   Schlom, Jeffrey ^a   Hodge, James W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTIIDIOTYPIC ANTIBODY; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; CANCER VACCINE; CHEMOKINE; CYCLOPHOSPHAMIDE; CYTOKINE; DENDRITIC CELL VACCINE; DOXORUBICIN; FLUOROURACIL; LIPOSOME; MAJOR HISTOCOMPATIBILITY ANTIGEN; MONOCLONAL ANTIBODY; PACLITAXEL; PLASMID DNA; TUMOR ANTIGEN; TUMOR CELL VACCINE;

ANTIGEN PRESENTING CELL; B CELL LYMPHOMA; CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PREVENTION; CANCER RADIOTHERAPY; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG TARGETING; FOWLPOX VIRUS; GENE EXPRESSION; HUMAN; IMMUNOGENICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; ONCOGENE RAS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR IMMUNITY; VACCINATION; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; WHOLE CELL;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CHEMISTRY, PHARMACEUTICAL; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; HUMANS; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES;

EID: 33745988889     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-230X(06)95004-0     Document Type: Review

References (170)

1. Abrams S.I., Dobrzanski M.J., Wells D.T., Stanziale S.F., Zaremba S., Masuelli L., Kantor J.A., Schlom J., and Masuelle L. Peptide-specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21. Eur. J. Immunol. 25 (1995) 2588-2597
2. Abrams S.I., Hand P.H., Tsang K.Y., and Schlom J. Mutant ras epitopes as targets for cancer vaccines. Semin. Oncol. 23 (1996) 118-134
3. Abrams S.I., Stanziale S.F., Lunin S.D., Zaremba S., and Schlom J. Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses. Eur. J. Immunol. 26 (1996) 435-443
4. Abrams S.I., Hodge J.W., McLaughlin J.P., Steinberg S.M., Kantor J.A., and Schlom J. Adoptive immunotherapy as an in vivo model to explore antitumor mechanisms induced by a recombinant anticancer vaccine. J. Immunother. 20 (1997) 48-59
5. Akagi J., Hodge J.W., McLaughlin J.P., Gritz L., Mazzara G., Kufe D., Schlom J., and Kantor J.A. Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7. J. Immunother. 20 (1997) 38-47
6. Allison J.P., Hurwitz A.A., and Leach D.R. Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr. Opin. Immunol. 7 (1995) 682-686
7. Banchereau J., Palucka A.K., Dhodapkar M., Burkeholder S., Taquet N., Rolland A., Taquet S., Coquery S., Wittkowski K.M., Bhardwaj N., Pineiro L., Steinman R., et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 61 (2001) 6451-6458
8. Banchereau J., Schuler-Thurner B., Palucka A.K., and Schuler G. Dendritic cells as vectors for therapy. Cell 106 (2001) 271-274
9. Baskar S., Azarenko V., Garcia Marshall E., Hughes E., and Ostrand-Rosenberg S. MHC class II-transfected tumor cells induce long-term tumor-specific immunity in autologous mice. Cell. Immunol. 155 (1994) 123-133
10. Bei R., Kantor J., Kashmiri S.V., Abrams S., and Schlom J. Enhanced immune responses and anti-tumor activity by baculovirus recombinant carcinoembryonic antigen (CEA) in mice primed with the recombinant vaccinia CEA. J. Immunother. Emphasis Tumor Immunol. 16 (1994) 275-282
11. Bendandi M., Gocke C.D., Kobrin C.B., Benko F.A., Sternas L.A., Pennington R., Watson T.M., Reynolds C.W., Gause B.L., Duffey P.L., Jaffe E.S., Creekmore S.P., et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med. 5 (1999) 1171-1177
12. Bergmann-Leitner E.S., and Abrams S.I. Differential role of Fas/Fas ligand interactions in cytolysis of primary and metastatic colon carcinoma cell lines by human antigen-specific CD8+ CTL. J. Immunol. 164 (2000) 4941-4954
13. Bhattacharya-Chatterjee M., Mukerjee S., Biddle W., Foon K.A., and Kohler H. Murine monoclonal anti-idiotype antibody as a potential network antigen for human carcinoembryonic antigen. J. Immunol. 145 (1990) 2758-2765
14. Bhattacharya-Chatterjee M., Chatterjee S.K., and Foon K.A. Anti-idiotype vaccine against cancer. Immunol. Lett. 74 (2000) 51-58
15. Bjorkman P.J. MHC restriction in three dimensions: A view of T cell receptor/ligand interactions. Cell 89 (1997) 167-170
16. Borrello I., and Pardoll D. GM-CSF-based cellular vaccines: A review of the clinical experience. Cytokine Growth Factor Rev. 13 (2002) 185-193
17. Briones J., Timmerman J.M., Panicalli D.L., and Levy R. Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules. J. Natl. Cancer Inst. 95 (2003) 548-555
18. Bystryn J.C. Vaccines for melanoma. Design strategies and clinical results. Dermatol. Clin. 16 (1998) 269-275
19. Carroll M.W., and Moss B. Poxviruses as expression vectors. Curr. Opin. Biotechnol. 8 (1997) 573-577
20. Chakraborty M., Abrams S.I., Camphausen K., Liu K., Scott T., Coleman C.N., and Hodge J.W. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J. Immunol. 170 (2003) 6338-6347
21. Chakraborty M., Abrams S.I., Coleman C.N., Camphausen K., Schlom J., and Hodge J.W. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res. 64 (2004) 4328-4337
22. Chappell D.B., Zaks T.Z., Rosenberg S.A., and Restifo N.P. Human melanoma cells do not express Fas (Apo-1/CD95) ligand. Cancer Res. 59 (1999) 59-62
23. Conry R.M., LoBuglio A.F., Kantor J., Schlom J., Loechel F., Moore S.E., Sumerel L.A., Barlow D.L., Abrams S., and Curiel D.T. Immune response to a carcinoembryonic antigen polynucleotide vaccine. Cancer Res. 54 (1994) 1164-1168
24. Conry R.M., LoBuglio A.F., and Curiel D.T. Polynucleotide-mediated immunization therapy of cancer. Semin. Oncol. 23 (1996) 135-147
25. Couch M., Saunders J.K., O'Malley Jr. B.W., Pardoll D., and Jaffee E. Genetically engineered tumor cell vaccine in a head and neck cancer model. Laryngoscope 113 (2003) 552-556
26. Crittenden M., Gough M., Harrington K., Olivier K., Thompson J., and Vile R.G. Expression of inflammatory chemokines combined with local tumor destruction enhances tumor regression and long-term immunity. Cancer Res. 63 (2003) 5505-5512
27. Curtiss III R., Kelly S.M., Tinge S.A., Tacket C.O., Levine M.M., Srinivasan J., and Koopman M. Recombinant Salmonella vectors in vaccine development. Dev. Biol. Stand. 82 (1994) 23-33
28. Darji A., Guzman C.A., Gerstel B., Wachholz P., Timmis K.N., Wehland J., Chakraborty T., and Weiss S. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell 91 (1997) 765-775
29. Davila E., Kennedy R., and Celis E. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res. 63 (2003) 3281-3288
30. Disis M.L., Bernhard H., Shiota F.M., Hand S.L., Gralow J.R., Huseby E.S., Gillis S., and Cheever M.A. Granulocyte-macrophage colony-stimulating factor: An effective adjuvant for protein and peptide-based vaccines. Blood 88 (1996) 202-210
31. Dranoff G. GM-CSF-based cancer vaccines. Immunol. Rev. 188 (2002) 147-154
32. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 4 (2004) 11-22
33. Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., Jackson V., Hamada H., Pardoll D., and Mulligan R.C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90 (1993) 3539-3543
34. Dudley M.E., and Rosenberg S.A. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat. Rev. Cancer 3 (2003) 666-675
35. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R., Restifo N.P., Hubicki A.M., Robinson M.R., Raffeld M., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298 (2002) 850-854
36. Emens L.A., and Jaffee E.M. Cancer vaccines: An old idea comes of age. Cancer Biol. Ther. 2 (2003) S161-S168
37. Esserman L.J., Lopez T., Montes R., Bald L.N., Fendly B.M., and Campbell M.J. Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice. Cancer Immunol. Immunother. 47 (1999) 337-342
38. Fearon E.R., Pardoll D.M., Itaya T., Golumbek P., Levitsky H.I., Simons J.W., Karasuyama H., Vogelstein B., and Frost P. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60 (1990) 397-403
39. Fenner F., Henderson D.A., Arita I., Jezek Z., and Ladnyi I.D. Smallpox and its Eradication (1988), World Health Organization, Geneva, Switzerland 10-14
40. Finn O.J. Cancer vaccines: Between the idea and the reality. Nat. Rev. Immunol. 3 (2003) 630-641
41. Finn O.J., Jerome K.R., Henderson R.A., Pecher G., Domenech N., Magarian-Blander J., and Barratt-Boyes S.M. MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol. Rev. 145 (1995) 61-89
42. Flanagan K., Glover R.T., Horig H., Yang W., and Kaufman H.L. Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response. Vaccine 22 (2004) 2894-2903
43. Foss F.M. Interleukin-2 fusion toxin: Targeted therapy for cutaneous T cell lymphoma. Ann. N.Y. Acad. Sci. 941 (2001) 166-176
44. Fry T.J., Moniuszko M., Creekmore S., Donohue S.J., Douek D.C., Giardina S., Hecht T.T., Hill B.J., Komschlies K., Tomaszewski J., Franchini G., and Mackall C.L. IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates. Blood 101 (2003) 2294-2299
45. Gansbacher B., Zier K., Daniels B., Cronin K., Bannerji R., and Gilboa E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172 (1990) 1217-1224
46. Garnett C.T., Palena C., Chakarborty M., Tsang K.Y., Schlom J., and Hodge J.W. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res. 64 (2004) 7985-7994
47. Gendler S.J., and Mukherjee P. Spontaneous adenocarcinoma mouse models for immunotherapy. Trends Mol. Med. 7 (2001) 471-475
48. Gilboa E. Immunotherapy of cancer with genetically modified tumor vaccines. Semin. Oncol. 23 (1996) 101-107
49. Gillies S.D., Lan Y., Wesolowski J.S., Qian X., Reisfeld R.A., Holden S., Super M., and Lo K.M. Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases. J. Immunol. 160 (1998) 6195-6203
50. Gilligan M.G., Knox P., Weedon S., Barton R., Kerr D.J., Searle P., and Young L.S. Adenoviral delivery of B7-1 (CD80) increases the immunogenicity of human ovarian and cervical carcinoma cells. Gene Ther. 5 (1998) 965-974
51. Gong J., Chen D., Kashiwaba M., Li Y., Chen L., Takeuchi H., Qu H., Rowse G.J., Gendler S.J., and Kufe D. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc. Natl. Acad. Sci. USA 95 (1998) 6279-6283
52. Greiner J.W., Zeytin H., Anver M.R., and Schlom J. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res. 62 (2002) 6944-6951
53. Harris D.T., Matyas G.R., Gomella L.G., Talor E., Winship M.D., Spitler L.E., and Mastrangelo M.J. Immunologic approaches to the treatment of prostate cancer. Semin. Oncol. 26 (1999) 439-447
54. Hodge J.W., and Schlom J. Comparative studies of a retrovirus versus a poxvirus vector in whole tumor-cell vaccines. Cancer Res. 59 (1999) 5106-5111
55. Hodge J.W., Abrams S., Schlom J., and Kantor J.A. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res. 54 (1994) 5552-5555
56. Hodge J.W., McLaughlin J.P., Abrams S.I., Shupert W.L., Schlom J., and Kantor J.A. Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity. Cancer Res. 55 (1995) 3598-3603
57. Hodge J.W., McLaughlin J.P., Kantor J.A., and Schlom J. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian poxvirus to enhance T-cell immunity and antitumor responses. Vaccine 15 (1997) 759-768
58. Hodge J.W., Sabzevari H., Yafal A.G., Gritz L., Lorenz M.G., and Schlom J. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res. 59 (1999) 5800-5807
59. Hodge J.W., Rad A.N., Grosenbach D.W., Sabzevari H., Yafal A.G., Gritz L., and Schlom J. Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules. J. Natl. Cancer. Inst. 92 (2000) 1228-1239
60. Hodge J.W., Grosenbach D.W., Aarts W.M., Poole D.J., and Schlom J. Vaccine therapy of established tumors in the absence of autoimmunity. Clin. Cancer Res. 9 (2003) 1837-1849
61. Hodge J.W., Chakraborty M., Kudo-Saito C., Garnett C.T., and Schlom J. Multiple costimulatory modalities enhance CTL avidity. J. Immunol. 174 (2005) 5994-6004
62. Hsu F.J., Benike C., Fagnoni F., Liles T.M., Czerwinski D., Taidi B., Engleman E.G., and Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2 (1996) 52-58
63. Hurwitz A.A., Townsend S.E., Yu T.F., Wallin J.A., and Allison J.P. Enhancement of the anti-tumor immune response using a combination of interferon-gamma and B7 expression in an experimental mammary carcinoma. Int. J. Cancer 77 (1998) 107-113
64. Hurwitz A.A., Yu T.F., Leach D.R., and Allison J.P. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl. Acad. Sci. USA 95 (1998) 10067-10071
65. Hurwitz A.A., Foster B.A., Kwon E.D., Truong T., Choi E.M., Greenberg N.M., Burg M.B., and Allison J.P. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 60 (2000) 2444-2448
66. Imboden M., Murphy K.R., Rakhmilevich A.L., Neal Z.C., Xiang R., Reisfeld R.A., Gillies S.D., and Sondel P.M. The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy. Cancer Res. 61 (2001) 1500-1507
67. Irvine K.R., Chamberlain R.S., Shulman E.P., Surman D.R., Rosenberg S.A., and Restifo N.P. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J. Natl. Cancer Inst. 89 (1997) 1595-1601
68. Iwasaki A., and Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5 (2004) 987-995
69. Jahrsdorfer B., and Weiner G.J. CpG oligodeoxynucleotides for immune stimulation in cancer immunotherapy. Curr. Opin. Investig. Drugs 4 (2003) 686-690
70. Johnston D., and Bystryn J.C. Heterogeneous antibody response to polyvalent melanoma vaccines in syngeneic mice. Cancer Immunol. Immunother. 54 (2005) 345-350
71. Johnston D., Reynolds S.R., and Bystryn J.C. Interleukin-2/liposomes potentiate immune responses to a soluble protein cancer vaccine in mice. Cancer Immunol. Immunother. 55 (2005) 1-8
72. Jones E., Dahm-Vicker M., Simon A.K., Green A., Powrie F., Cerundolo V., and Gallimore A. Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun. 2 (2002) 1
73. Karanikas V., Thynne G., Mitchell P., Ong C.S., Gunawardana D., Blum R., Pearson J., Lodding J., Pietersz G., Broadbent R., Tait B., and McKenzie I.F. Mannan mucin-1 peptide immunization: Influence of cyclophosphamide and the route of injection. J. Immunother. 24 (2001) 172-183
74. Kass E., Schlom J., Thompson J., Guadagni F., Graziano P., and Greiner J.W. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res. 59 (1999) 676-683
75. Kass E., Panicali D.L., Mazzara G., Schlom J., and Greiner J.W. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res. 61 (2001) 206-214
76. Kaufmann S.H., and Hess J. Impact of intracellular location of and antigen display by intracellular bacteria: Implications for vaccine development. Immunol. Lett. 65 (1999) 81-84
77. Klebanoff C.A., Finkelstein S.E., Surman D.R., Lichtman M.K., Gattinoni L., Theoret M.R., Grewal N., Spiess P.J., Antony P.A., Palmer D.C., Tagaya Y., Rosenberg S.A., et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc. Natl. Acad. Sci. USA 101 (2004) 1969-1974
78. Kobayashi H., Wood M., Song Y., Appella E., and Celis E. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. Cancer Res. 60 (2000) 5228-5236
79. Kobayashi H., Lu J., and Celis E. Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen. Cancer Res. 61 (2001) 7577-7584
80. Kobayashi H., Omiya R., Ruiz M., Huarte E., Sarobe P., Lasarte J.J., Herraiz M., Sangro B., Prieto J., Borras-Cuesta F., and Celis E. Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen. Clin. Cancer Res. 8 (2002) 3219-3225
81. Koido S., Tanaka Y., Chen D., Kufe D., and Gong J. The kinetics of in vivo priming of CD4 and CD8 T cells by dendritic/tumor fusion cells in MUC1-transgenic mice. J. Immunol. 168 (2002) 2111-2117
82. Krieg A.M. Immune effects and mechanisms of action of CpG motifs. Vaccine 19 (2000) 618-622
83. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20 (2002) 709-760
84. Kudo-Saito C., Schlom J., and Hodge J.W. Intratumoral vaccination and diversified subcutaneous/intratumoral vaccination with recombinant poxviruses encoding a tumor antigen and multiple costimulatory molecules. Clin. Cancer Res. 10 (2004) 1090-1099
85. Kudo-Saito C., Schlom J., and Hodge J.W. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors. Clin. Cancer Res. 11 (2005) 4533-4544
86. Kusmartsev S., and Gabrilovich D.I. Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol. Immunother. 51 (2002) 293-298
87. Kwak L.W., Campbell M.J., Czerwinski D.K., Hart S., Miller R.A., and Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. 327 (1992) 1209-1215
88. Kwak L.W., Thielemans K., and Massaia M. Idiotypic vaccination as therapy for multiple myeloma. Semin. Hematol. 36 (1999) 34-37
89. Liso A., Stockerl-Goldstein K.E., Auffermann-Gretzinger S., Benike C.J., Reichardt V., van Beckhoven A., Rajapaksa R., Engleman E.G., Blume K.G., and Levy R. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol. Blood Marrow Transplant. 6 (2000) 621-627
90. Liu B., DeFilippo A.M., and Li Z. Overcoming immune tolerance to cancer by heat shock protein vaccines. Mol. Cancer Ther. 1 (2002) 1147-1151
91. Lode H.N., Xiang R., Duncan S.R., Theofilopoulos A.N., Gillies S.D., and Reisfeld R.A. Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12. Proc. Natl. Acad. Sci. USA 96 (1999) 8591-8596
92. Lu Y., Bellgrau D., Dwyer-Nield L.D., Malkinson A.M., Duke R.C., Rodell T.C., and Franzusoff A. Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy. Cancer Res. 64 (2004) 5084-5088
93. Lutsiak M.E., Semnani R.T., De Pascalis R., Kashmiri S.V., Schlom J., and Sabzevari H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105 (2005) 2862-2868
94. MacLean G.D., Miles D.W., Rubens R.D., Reddish M.A., and Longenecker B.M. Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J. Immunother. Emphasis Tumor Immunol. 19 (1996) 309-316
95. Mandelboim O., Vadai E., Fridkin M., Katz-Hillel A., Feldman M., Berke G., and Eisenbach L. Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. Nat. Med. 1 (1995) 1179-1783
96. Medzhitov R. CpG DNA: Security code for host defense. Nat. Immunol. 2 (2001) 15-16
97. Melero I., Bach N., and Chen L. Costimulation, tolerance and ignorance of cytolytic T lymphocytes in immune responses to tumor antigens. Life Sci. 60 (1997) 2035-2041
98. Merad M., Sugie T., Engleman E.G., and Fong L. In vivo manipulation of dendritic cells to induce therapeutic immunity. Blood 99 (2002) 1676-1682
99. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc. Natl. Acad. Sci. USA 93 (1996) 11341-11348
100. Murata K., Garcia-Sastre A., Tsuji M., Rodrigues M., Rodriguez D., Rodriguez J.R., Nussenzweig R.S., Palese P., Esteban M., and Zavala F. Characterization of in vivo primary and secondary CD8+ T cell responses induced by recombinant influenza and vaccinia viruses. Cell Immunol. 173 (1996) 96-107
101. Nair S.K., Morse M., Boczkowski D., Cumming R.I., Vasovic L., Gilboa E., and Lyerly H.K. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann. Surg. 235 (2002) 540-549
102. Neal Z.C., Yang J.C., Rakhmilevich A.L., Buhtoiarov I.N., Lum H.E., Imboden M., Hank J.A., Lode H.N., Reisfeld R.A., Gillies S.D., and Sondel P.M. Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy. Clin. Cancer Res. 10 (2004) 4839-4847
103. Nelson K.A., George E., Swenson C., Forstrom J.W., and Hellstrom K.E. Immunotherapy of murine sarcomas with auto-anti-idiotypic monoclonal antibodies which bind to tumor-specific T cells. J. Immunol. 139 (1987) 2110-2117
104. Nikitina E.Y., Chada S., Muro-Cacho C., Fang B., Zhang R., Roth J.A., and Gabrilovich D.I. An effective immunization and cancer treatment with activated dendritic cells transduced with full-length wild-type p53. Gene Ther. 9 (2002) 345-352
105. Noguchi Y., Chen Y.T., and Old L.J. A mouse mutant p53 product recognized by CD4+ and CD8+ T cells. Proc. Natl. Acad. Sci. USA 91 (1994) 3171-3175
106. Oh S., Hodge J.W., Ahlers J.D., Burke D.S., Schlom J., and Berzofsky J.A. Selective induction of high avidity CTL by altering the balance of signals from APC. J. Immunol. 170 (2003) 2523-2530
107. Okamoto M., and Sato M. Toll-like receptor signaling in anti-cancer immunity. J. Med. Invest. 50 (2003) 9-24
108. Overwijk W.W., Theoret M.R., Finkelstein S.E., Surman D.R., de Jong L.A., Vyth-Dreese F.A., Dellemijn T.A., Antony P.A., Spiess P.J., Palmer D.C., Heimann D.M., Klebanoff C.A., et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198 (2003) 569-580
109. Paglia P., Medina E., Arioli I., Guzman C.A., and Colombo M.P. Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium, results in protective immunity against a murine fibrosarcoma. Blood 92 (1998) 3172-3176
110. Palena C., Foon K.A., Panicali D., Yafal A.G., Chinsangaram J., Hodge J.W., Schlom J., and Tsang K.Y. Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): Enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules. Blood 106 (2005) 3515-3523
111. Paoletti E. Applications of pox virus vectors to vaccination: An update. Proc. Natl. Acad. Sci. USA 93 (1996) 11349-11353
112. Pardoll D. Does the immune system see tumors as foreign or self?. Annu. Rev. Immunol. 21 (2003) 807-839
113. Pardoll D.M. Cancer vaccines. Nat. Med. 4 (1998) 525-531
114. Pardoll D.M., and Beckerleg A.M. Exposing the immunology of naked DNA vaccines. Immunity 3 (1995) 165-169
115. Pardoll D.M., and Topalian S.L. The role of CD4+ T cell responses in antitumor immunity. Curr. Opin. Immunol. 10 (1998) 588-594
116. Parkhurst M.R., Salgaller M.L., Southwood S., Robbins P.F., Sette A., Rosenberg S.A., and Kawakami Y. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol. 157 (1996) 2539-2548
117. Pertl U., Luster A.D., Varki N.M., Homann D., Gaedicke G., Reisfeld R.A., and Lode H.N. IFN-gamma-inducible protein-10 is essential for the generation of a protective tumor-specific CD8 T cell response induced by single-chain IL-12 gene therapy. J. Immunol. 166 (2001) 6944-6951
118. Pervin S., Chakraborty M., Bhattacharya-Chatterjee M., Zeytin H., Foon K.A., and Chatterjee S.K. Induction of antitumor immunity by an anti-idiotype antibody mimicking carcinoembryonic antigen. Cancer Res. 57 (1997) 728-734
119. Prasad S.J., Farrand K.J., Matthews S.A., Chang J.H., McHugh R.S., and Ronchese F. Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4+CD25+ regulatory T cells. J. Immunol. 174 (2005) 90-98
120. Prud'homme G.J. DNA vaccination against tumors. J. Gene Med. 1 (2005) 3-17
121. Reichardt V.L., Okada C.Y., Liso A., Benike C.J., Stockerl-Goldstein K.E., Engleman E.G., Blume K.G., and Levy R. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-a feasibility study. Blood 93 (1999) 2411-2419
122. Restifo N.P., and Rosenberg S.A. Developing recombinant and synthetic vaccines for the treatment of melanoma. Curr. Opin. Oncol. 11 (1999) 50-57
123. Ribas A., Timmerman J.M., Butterfield L.H., and Economou J.S. Determinant spreading and tumor responses after peptide-based cancer immunotherapy. Trends Immunol. 24 (2003) 58-61
124. Rolph M.S., and Ramshaw I.A. Recombinant viruses as vaccines and immunological tools. Curr. Opin. Immunol. 9 (1997) 517-524
125. Rosenberg S.A. Progress in the development of immunotherapy for the treatment of patients with cancer. J. Intern. Med. 250 (2001) 462-475
126. Ross H.M., Weber L.W., Wang S., Piskun G., Dyall R., Song P., Takechi Y., Nikolic-Zugic J., Houghton A.N., and Lewis J.J. Priming for T-cell-mediated rejection of established tumors by cutaneous DNA immunization. Clin. Cancer Res. 3 (1997) 2191-2196
127. Roth A., Rohrbach F., Weth R., Frisch B., Schuber F., and Wels W.S. Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct. Br. J. Cancer 92 (2005) 1421-1429
128. Rubio V., Stuge T.B., Singh N., Betts M.R., Weber J.S., Roederer M., and Lee P.P. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat. Med. 9 (2003) 1377-1382
129. Ruffini P.A., and Kwak L.W. Immunotherapy of multiple myeloma. Semin. Hematol. 38 (2001) 260-267
130. Sakai Y., Morrison B.J., Burke J.D., Park J.M., Terabe M., Janik J.E., Forni G., Berzofsky J.A., and Morris J.C. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice. Cancer Res. 64 (2004) 8022-8028
131. Salazar E., Zaremba S., Arlen P.M., Tsang K.Y., and Schlom J. Agonist peptide from a cytotoxic t-lymphocyte epitope of human carcinoembryonic antigen stimulates production of tc1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide. Int. J. Cancer 85 (2000) 829-838
132. Samanci A., Yi Q., Fagerberg J., Strigard K., Smith G., Ruden U., Wahren B., and Mellstedt H. Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen. Cancer Immunol. Immunother. 47 (1998) 131-142
133. Schneeberger A., Luhrs P., Kutil R., Steinlein P., Schild H., Schmidt W., and Stingl G. Granulocyte-macrophage colony-stimulating factor-based melanoma cell vaccines immunize syngeneic and allogeneic recipients via host dendritic cells. J. Immunol. 171 (2003) 5180-5187
134. Schodel F., and Curtiss III R. Salmonellae as oral vaccine carriers. Dev. Biol. Stand. 84 (1995) 245-253
135. Schultze J., Nadler L.M., and Gribben J.G. B7-mediated costimulation and the immune response. Blood Rev. 10 (1996) 111-127
136. Schwartz R.H. Models of T cell anergy: Is there a common molecular mechanism?. J. Exp. Med. 184 (1996) 19-29
137. Serafini P., De Santo C., Marigo I., Cingarlini S., Dolcetti L., Gallina G., Zanovello P., and Bronte V. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol. Immunother. 53 (2004) 64-72
138. Shibata M.A., Jorcyk C.L., Liu M.L., Yoshidome K., Gold L.G., and Green J.E. The C3(1)/SV40 T antigen transgenic mouse model of prostate and mammary cancer. Toxicol. Pathol. 26 (1998) 177-182
139. Shimizu J., Yamazaki S., and Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: A common basis between tumor immunity and autoimmunity. J. Immunol. 163 (1999) 5211-5218
140. Soares M.M., Mehta V., and Finn O.J. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. J. Immunol. 166 (2001) 6555-6563
141. Steinman R.M., and Dhodapkar M. Active immunization against cancer with dendritic cells: The near future. Int. J. Cancer 94 (2001) 459-473
142. Sugai S., Palmer D.W., Talal N., and Witz I.P. Protective and cellular immune responses to idiotypic determinants on cells from a spontaneous lymphoma of NZB-NZW F1 mice. J. Exp. Med. 140 (1974) 1547-1558
143. Surman D.R., Dudley M.E., Overwijk W.W., and Restifo N.P. Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. J. Immunol. 164 (2000) 562-565
144. Swain S.L., Croft M., Dubey C., Hayes L., Rogers P., Zhang X., and Bradley L.M. From naive to memory T cells. Immunol. Rev. 150 (1996) 143-167
145. Taieb J., Chaput N., and Zitvogel L. Dendritic cell-derived exosomes as cell-free peptide-based vaccines. Crit. Rev. Immunol. 25 (2005) 215-223
146. Terando A., and Mule J.J. On combining antineoplastic drugs with tumor vaccines. Cancer Immunol. Immunother. 52 (2003) 680-685
147. Terasawa H., Tsang K.Y., Gulley J., Arlen P., and Schlom J. Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen. Clin. Cancer Res. 8 (2002) 41-53
148. Thomas M.C., Greten T.F., Pardoll D.M., and Jaffee E.M. Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine. Hum. Gene Ther. 9 (1998) 835-843
149. Townsend S.E., and Allison J.P. Tumor rejection after direct costimulation of CD8+ T cells by B7- transfected melanoma cells. Science 259 (1993) 368-370
150. Triozzi P.L., Aldrich W., Allen K.O., Lima J., Shaw D.R., and Strong T.V. Antitumor activity of the intratumoral injection of fowlpox vectors expressing a triad of costimulatory molecules and granulocyte/macrophage colony stimulating factor in mesothelioma. Int. J. Cancer. 113 (2005) 406-414
151. Tsang K.Y., Zhu M., Even J., Gulley J., Arlen P., and Schlom J. The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells. Cancer Res. 61 (2001) 7568-7576
152. Tsang K.Y., Palena C., Gulley J., Arlen P., and Schlom J. A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1. Clin. Cancer Res. 10 (2004) 2139-2149
153. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., Gromkowski S.H., Deck R.R., DeWitt C.M., Friedman A., Hawe L.A., Leander K.R., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259 (1993) 1745-1749
154. Valmori D., Dutoit V., Ayyoub M., Rimoldi D., Guillaume P., Lienard D., Lejeune F., Cerottini J.C., Romero P., and Speiser D.E. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine. Cancer Immun. 3 (2003) 15
155. Van Parijs L., and Abbas A.K. Homeostasis and self-tolerance in the immune system: Turning lymphocytes off. Science 280 (1998) 243-248
156. Vincent-Schneider H., Stumptner-Cuvelette P., Lankar D., Pain S., Raposo G., Benaroch P., and Bonnerot C. Exosomes bearing HLA-DR1 molecules need dendritic cells to efficiently stimulate specific T cells. Int. Immunol. 14 (2002) 713-722
157. Waldmann T.A., Dubois S., and Tagaya Y. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: Implications for immunotherapy. Immunity 14 (2001) 105-110
158. Weiskirch L.M., and Paterson Y. Listeria monocytogenes: A potent vaccine vector for neoplastic and infectious disease. Immunol. Rev. 158 (1997) 159-169
159. Widmann C., Romero P., Maryanski J.L., Corradin G., and Valmori D. T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides. J. Immunol. Methods 155 (1992) 95-99
160. Wigginton J.M., Park J.W., Gruys M.E., Young H.A., Jorcyk C.L., Back T.C., Brunda M.J., Strieter R.M., Ward J., Green J.E., and Wiltrout R.H. Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by IL-12/pulse IL-2: Induction of local T cell infiltration, Fas/Fas ligand gene expression, and mammary epithelial apoptosis. J. Immunol. 166 (2001) 1156-1168
161. Wilson M., Seymour R., and Henderson B. Bacterial perturbation of cytokine networks. Infect. Immun. 66 (1998) 2401-2409
162. Wingren A.G., Parra E., Varga M., Kalland T., Sjogren H.O., Hedlund G., and Dohlsten M. T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles. Crit. Rev. Immunol. 15 (1995) 235-253
163. Wolpoe M.E., Lutz E.R., Ercolini A.M., Murata S., Ivie S.E., Garrett E.S., Emens L.A., Jaffee E.M., and Reilly R.T. HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice. J. Immunol. 171 (2003) 2161-2169
164. Wooldridge J.E., and Weiner G.J. CpG DNA and cancer immunotherapy: Orchestrating the antitumor immune response. Curr. Opin. Oncol. 15 (2003) 440-445
165. Xiang R., Lode H.N., Dreier T., Gillies S.D., and Reisfeld R.A. Induction of persistent tumor-protective immunity in mice cured of established colon carcinoma metastases. Cancer Res. 58 (1998) 3918-3925
166. Yang A.S., Monken C.E., and Lattime E.C. Intratumoral vaccination with vaccinia-expressed tumor antigen and granulocyte macrophage colony-stimulating factor overcomes immunological ignorance to tumor antigen. Cancer Res. 63 (2003) 6956-6961
167. Yang S., Tsang K.Y., and Schlom J. Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells. Clin. Cancer Res. 11 (2005) 5603-5615
168. Zaremba S., Barzaga E., Zhu M., Soares N., Tsang K.Y., and Schlom J. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res. 57 (1997) 4570-4577
169. Zeng G., Touloukian C.E., Wang X., Restifo N.P., Rosenberg S.A., and Wang R.F. Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J. Immunol. 165 (2000) 1153-1159
170. Zhu M., Terasawa H., Gulley J., Panicali D., Arlen P., Schlom J., and Tsang K.Y. Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells. Cancer Res. 61 (2001) 3725-3734